Ecnoglutide
InvestigationalA long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.
XW003 · Sciwind GLP-1
6 human studies
- Preclinical
- 40%
- Human research
- 60%
Based on 10 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
How It Works (Simplified)
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist designed for once-weekly subcutaneous injection. It mimics the incretin hormone GLP-1 to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. Developed by Sciwind Biosciences, it represents China’s entry into the competitive GLP-1 obesity therapeutics market.
Scientific Pathways
GLP-1 Receptor Activation: Like other GLP-1 receptor agonists, ecnoglutide binds to and activates GLP-1 receptors in the pancreas, brain, and GI tract. This triggers multiple downstream effects: enhanced insulin secretion (glucose-dependent), suppressed glucagon release, delayed gastric emptying, and central satiety signaling in the hypothalamus.
Engineering for Duration: Ecnoglutide incorporates structural modifications to resist DPP-4 enzymatic degradation and extend half-life, enabling once-weekly dosing comparable to semaglutide.
Clinical Evidence
Phase 3 Weight Loss Data: A Phase 3 trial conducted in Chinese adults with overweight or obesity (without diabetes) demonstrated 13.2% body weight reduction at 40 weeks with ecnoglutide at the highest dose (2.4 mg once weekly), versus essentially no change on placebo. The efficacy is competitive with first-generation weekly GLP-1 agonists, though direct head-to-head comparisons against other obesity agents are not yet available.
Glycemic Control: Phase 3 data also showed significant HbA1c reduction in patients with type 2 diabetes, supporting potential dual indications for obesity and diabetes.
Safety Profile
The safety profile is consistent with the GLP-1 receptor agonist class, with gastrointestinal adverse events (nausea, vomiting, diarrhea) as the most common side effects. No unique safety signals beyond the established GLP-1 class effects have been reported. Safety data is primarily from Chinese patient populations; global generalizability awaits broader trials.
Important Limitations
- Phase 3 data primarily from Chinese populations; global applicability uncertain
- No FDA submission planned in the near term
- Weight loss (13.2% at 40 weeks) trails leading competitors (semaglutide ~15-17%, tirzepatide ~20-26%)
- No head-to-head trials against established GLP-1 therapies
- Not available outside clinical trials in China
- Limited English-language publication of trial data
Semaglutide
AvoidBoth are GLP-1 receptor agonists. Co-administration would provide redundant GLP-1 agonism with increased risk of GI adverse events.
Tirzepatide
AvoidBoth target GLP-1 receptors. Combining would create overlapping mechanisms with increased adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Ecnoglutide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191
AOD-9604 is a modified human-growth-hormone fragment investigated for obesity and fat metabolism. Its obesity development program did not establish efficacy, and current regulatory sources identify major safety and quality gaps for unapproved or compounded products.
Cagrilintide
AM833 · NN9838
Investigational long-acting amylin analogue. REDEFINE 1 included a Phase 3 cagrilintide-only arm; Novo reports 11.8% mean weight loss versus 2.3% with placebo at 68 weeks using an on-treatment estimand. Dedicated RENEW Phase 3 monotherapy trials have started. Cagrilintide is also a CagriSema component.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
Investigational fixed-dose cagrilintide plus semaglutide combination. Novo filed a US obesity NDA in December 2025. Its sponsor-reported REDEFINE 4 head-to-head trial missed non-inferiority versus tirzepatide; September 2026 REIMAGINE 5 and REDEFINE 9 toplines address different populations and doses. A filing and positive toplines are not FDA approval.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.